Sat, October 12, 2024
AUS Edition NZ Edition UK Edition CA Edition USA Edition FRA Edition GER Edition ESP Edition ITA Edition NLD Edition
PRT Edition SWE Edition GRC Edition IND Edition POL Edition BRA Edition ZAF Edition RUS Edition CHN Edition UAE Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. IMU
Healthcare
Facebook Twitter Linkedin

Imugene Ltd (ASX:IMU)

0.048 AUD

0.000 0.000%
Last Updated at: 2024-10-11T03:13:00Z

Imugene Ltd

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy CHECKvacc in phase 1 clinical trial for triple negative breast cancer; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic and advanced gastric cancer; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. The company has a research collaboration with NeoImmuneTech to enhance cancer treatments. Imugene Limited is based in Sydney, Australia.

4-6 Bligh Street, Sydney, NSW, Australia, 2000

61 2 9423 0881

https://www.imugene.com

Key Executives

Sr. No. Name Title Year Born
1. Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Exec. Chairman 1956
2. Ms. Leslie Chong CEO, MD & Exec. Director NA
3. Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. Chief Technology Officer NA
4. Dr. Monil Shah M.B.A., Pharm.D. Chief Bus. Officer NA
5. Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD Chief Financial Officer 1966
6. Ms. Ursula McCurry Sr. VP of Clinical Operations NA
7. Dr. Giovanni Selvaggi Chief Medical Officer NA
8. Mr. Nathan Jong C.A. Joint Company Sec. NA
9. Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956
10. Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Executive Chairman 1956

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
CSL

CSL Ltd

 +1.080 0.367% 293.56 36.670 31.949 9.623 5.594 7.328 22.744
TLX

Telix Pharmaceuticals Ltd

 -0.060 0.284% 21.14 139.200 21.008 10.714 17.174 10.739 93.760
CU6

Clarity Pharmaceuticals Ltd

 -0.230 3.230% 7.01 0.000 0.000 213.080 17.240 0.000 -0.779
NEU

Neuren Pharmaceuticals Ltd

 -0.270 2.055% 13.03 14.130 35.211 8.840 5.319 6.770 8.824

Income Statement

(Currency in AUD)
Breakdown 30-06-2023 30-06-2022 30-06-2021 30-06-2020 30-06-2019
Income Before Tax -39.171M -37.869M -18.455M -10.508M -7.775M
Minority Interest - - - - -
Net Income -39.171M -37.976M -25.767M -14.587M -7.776M
Selling General Administrative 17.766M 12.097M 9.438M 4.293M 3.806M
Gross Profit - - - - 4.127M
Reconciled Depreciation 0.19M 0.203M 0.104M 0.082M 0.063M
Ebit -51.291M -37.658M -18.344M -10.503M -7.769M
Ebitda -51.1M -37.454M -18.24M -10.42M -7.706M
Depreciation And Amortization 0.19M 0.203M 0.104M 0.082M 0.063M
Operating Income -51.291M -37.658M -18.344M -10.503M -7.769M
Other Operating Expenses 51.293M 50.673M 25.666M 14.879M 12.389M
Interest Expense - 0.107M 0.111M 0.005M 0.006M
Tax Provision 0M 0M 0M 0M 0M
Interest Income 1.88M 0.192M 0.127M 0.297M 0.415M
Net Interest Income 1.852M 0.072M 0.011M 0.297M 0.409M
Income Tax Expense -1.85M 0.107M 7.311M 4.079M 0M
Total Revenue - 0M 0M 4.21M 4.542M
Total Operating Expenses 51.293M 50.673M 25.666M 14.879M 12.389M
Cost Of Revenue - - - - -
Total Other Income Expense Net 10.27M -0.212M -0.111M -0.005M -0.006M
Net Income From Continuing Ops -39.171M -37.869M -18.455M -10.508M -7.775M
Net Income Applicable To Common Shares -37.915M -37.869M -18.455M -10.508M -7.775M

Balance Sheet

(Currency in AUD)
Breakdown 30-06-2024 30-06-2023 30-06-2022 30-06-2021 30-06-2020
Total Assets 151.398M 195.807M 147.606M 71.809M 65.205M
Intangible Assets 34.12M 30.486M 32.689M 34.893M 30.458M
Other Current Assets 7.308M 0.402M 1.11M 0.17M 0.194M
Total Liab 33.143M 7.437M 8.901M 6.791M 5.399M
Total Stockholder Equity 118.254M 188.37M 138.705M 65.018M 59.806M
Other Current Liab 22.418M 1.923M 1.423M 2.853M 1.435M
Common Stock 370.313M 314.402M 230.789M 113.107M 92.798M
Capital Stock 370.313M 314.402M 230.789M 113.107M 104.895M
Retained Earnings -289.832M -142.692M -103.521M -65.652M -47.31M
Good Will - - - - -
Other Assets - 0.019M 0.035M 0.016M 0.016M
Cash 93.108M 153.151M 99.888M 29.487M 30.107M
Cash And Equivalents - 49.543M 29M 21.001M 25.001M
Total Current Liabilities 29.299M 6.084M 7.425M 4.457M 2.899M
Current Deferred Revenue - 1.629M 1.304M 0.738M 0.391M
Net Debt -91.561M -152.597M -99.214M -29.216M -30.037M
Short Term Debt 0.912M 0.191M 0.184M 0.106M 0.061M
Short Long Term Debt - - - - -
Short Long Term Debt Total 1.547M 0.553M 0.673M 0.271M 0.069M
Other Stockholder Equity - -172.966M -127.268M -47.455M -45.487M
Property Plant Equipment - 0.683M 0.863M 0.466M 0.156M
Total Current Assets 113.034M 164.401M 113.766M 36.319M 34.495M
Long Term Investments 2.413M 0.218M 0.252M 0.115M 0.081M
Short Term Investments 1.435M - -0M - -
Net Receivables 12.619M 10.849M 12.768M 6.662M 4.194M
Long Term Debt - - - - -
Inventory - - - - -
Accounts Payable 5.968M 2.341M 4.513M 0.76M 1.013M
Accumulated Other Comprehensive Income 37.773M 16.66M 11.437M 17.563M 14.319M
Non Currrent Assets Other 0.133M 0.019M 0.035M 0.016M 0.016M
Non Current Assets Total 38.364M 31.405M 33.84M 35.49M 30.71M
Capital Lease Obligations - 0.553M 0.673M 0.271M 0.069M
Long Term Debt Total - 0.362M 0.489M 0.165M 0.008M

Cash Flow

(Currency in AUD)
Breakdown 30-06-2023 30-06-2022 30-06-2021 30-06-2020 30-06-2019
Investments 1.889M -0.137M -0.035M -0.031M -0.03M
Total Cashflows From Investing Activities 1.889M -0.221M -5.326M -1.207M 0.247M
Total Cash From Financing Activities 82.981M 101.341M 17.985M 22.707M 18.773M
Net Income -37.915M -37.869M -18.455M -10.508M -7.776M
Change In Cash 53.263M 70.401M -0.62M 11.059M 11.226M
Begin Period Cash Flow 99.888M 29.487M 30.107M 19.048M 7.822M
End Period Cash Flow 153.151M 99.888M 29.487M 30.107M 19.048M
Total Cash From Operating Activities -31.471M -30.848M -13.28M -10.438M -7.909M
Depreciation 2.393M 2.407M 1.962M 0.082M 0.063M
Other Cashflows From Investing Activities 1.889M 0.174M 0.156M 0.311M 0.405M
Dividends Paid - - - - -
Change To Inventory - - - - -
Sale Purchase Of Stock -5.042M -6.151M -0.126M -1.801M -1.444M
Other Cashflows From Financing Activities -0.147M -1.385M 0.063M -0.059M -0.047M
Capital Expenditures 0M 0.277M 5.448M 1.487M 0.144M
Change In Working Capital 1.089M -6.108M -2.455M -0.034M 1.868M
Other Non Cash Items 4.051M 4.614M 3.213M -0.012M 7.712M
Free Cash Flow -31.471M -31.125M -18.728M -11.924M -8.053M

Funds

Sr. No. Name Purchased On Shares
1. DFA International Sustainability Core 1 Portfolio 3 years ago 1293602
Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App